A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis

Key Points

• The aim is to evaluate the safety and effects of YAQ007 on ammonia levels in cirrhosis.
• Phase 2a randomized open-label design
• Comparison of YAQ007 and rifaximin
• Doses of YAQ007 were ≥4 g BID
• YAQ007 showed short-term ammonia-lowering activity
• Results suggest potential for further clinical evaluation
• Findings are exploratory and hypothesis-generating